August 26, 2025

Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September

LONDON, Aug. 26, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immune response detection and diagnostics, today announced it has signed a Research Services Agreement ("RSA") with Emory University's Center for the Advancement of Diagnostics for a Just Society ("ADJUST Center") to conduct clinical studies of ViraxImmune™. These studies will focus on immune profiling in individuals with post-viral syndromes, beginning with post-acute sequelae of SARS-CoV-2 ("PASC"), commonly known as long COVID.

Under the agreement, the Emory Laboratory for Innovative Assay Development ("ELIAD") will conduct patient recruitment, testing, and analysis to generate clinical data. This data is intended to support Virax's planned regulatory submissions and potential future commercial rollout.

This collaboration aligns with Virax's preparations for a pre-submission meeting with the U.S. Food and Drug Administration ("FDA") in early September 2025. The meeting will seek the FDA's feedback on the proposed intended use and regulatory pathway for ViraxImmune™ in PASC. The outcome will provide formal input on the pivotal U.S. clinical trial design and inform the Company's regulatory and commercialisation strategy.

"Partnering with Emory University, one of the foremost institutions in immunology and clinical research, is an important step toward validating ViraxImmune™ in real-world patient populations," said James Foster, Chief Executive Officer of Virax Biolabs. "With millions suffering from long COVID and other post-viral conditions without effective diagnostic options, we believe ViraxImmune™ is uniquely positioned to fill this gap. This collaboration advances our broader U.S. market entry strategy and represents a significant opportunity to create long-term value for our shareholders as we work to establish Virax as a leader in immune profiling diagnostics."

Dr. Wilbur A. Lam, MD, PhD, Professor of Pediatrics and Biomedical Engineering at Emory University and Georgia Tech, and Director of the ADJUST Center, commented: "PASC and other post-viral syndromes remain poorly understood and underdiagnosed. Immune profiling technologies could provide critical insights into patient immune function, enabling more precise diagnosis and potentially guiding treatment strategies."

ViraxImmune™ is a proprietary T cell testing technology designed to evaluate a patient's immune response profile. Unlike conventional antibody testing, it assesses T cell reactivity to provide a more comprehensive picture of immune health in chronic and post-viral conditions.

About Virax Biolabs Group Limited

Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T cell-based test technologies with the intention of providing an immunology profiling platform. T cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as long COVID and other chronic conditions linked to immune dysregulation.

For more information, please visit **www.viraxbiolabs.com**.

About Emory University

Emory University is a leading research institution based in Atlanta, Georgia, recognised internationally for its contributions to medical innovation, patient care, and scientific discovery. Emory's School of Medicine and affiliated healthcare network are at the forefront of translational research, with particular strengths in infectious diseases, immunology, and clinical trial execution.

Caution Concerning Forward Looking Statements:

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Virax's Annual Report on Form 20-F for the year ended March 31, 2025. Although we believe the expectations reflected in such forward-looking statements are reasonable, we

can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-partners-with-emory-university-on-viraximmune-clinical-studies-readies-for-fda-pre-submission-meeting-in-early-september-302537678.html

SOURCE Virax BioLabs Group Limited